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Genetic Targeting of ERK1 Suggests a Predominant Role for
ERK2 in Murine Pain Models
Benedict J. Alter,1 Chengshui Zhao,1 Farzana Karim,1 Gary E. Landreth,2 and Robert W. Gereau IV1
1Washington University Pain Center and Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri 63110, and
2Department of Neurosciences, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106
The extracellular signal-regulated kinase (ERK) isoforms, ERK1 and ERK2, are believed to be key signalingmolecules in nociception and
nociceptive sensitization. Studies using inhibitors targeting the shared ERK1/2 upstream activator, mitogen-activated protein kinase
kinase (MEK), and transgenic mice expressing a dominant-negative form of MEK have established the importance of ERK1/2 signaling.
However, these techniques do not discriminate between ERK1 and ERK2. To dissect the function of each isoform in pain, we used mice
with a targeted genetic deletion of ERK1 [ERK1 knock-out (KO)] to test the hypothesis that ERK1 is required for behavioral sensitization
in rodent pain models. Despite activation (phosphorylation) of ERK1 after acute noxious stimulation and in models of chronic pain, we
found that ERK1was not required for formalin-induced spontaneous behaviors, complete Freund’s adjuvant-induced heat andmechan-
ical hypersensitivity, and spared nerve injury-inducedmechanical hypersensitivity. However, ERK1deletion did delay formalin-induced
long-term heat hypersensitivity, without affecting formalin-induced mechanical hypersensitivity, suggesting that ERK1 partially
shapes long-term responses to formalin. Interestingly, ERK1 deletion resulted in elevated basal ERK2 phosphorylation. However,
this did not appear to influence nociceptive processing, since inflammation-induced ERK2 phosphorylation and pERK1/2 immu-
noreactivity in spinal cord were not elevated in ERK1 KO mice. Additionally, systemic MEK inhibition with SL327 (-[amino[(4-
aminophenyl)thio]methylene]-2-(trifluoromethyl)benzeneacetonitrile) attenuated formalin-induced spontaneous behaviors similarly
in wild-type and ERK1 KO mice, indicating that unrelated signaling pathways do not functionally compensate for the loss of ERK1.
Together, these results suggest that ERK1 plays a limited role in nociceptive sensitization and support a predominant role for ERK2 in
these processes.
Introduction
Extracellular signal-regulated kinases (ERKs), ERK1 and ERK2,
are mitogen-activated protein kinases (MAPKs) (Pearson et al.,
2001) that have been identified as critical players in sensitization
to noxious stimuli after peripheral inflammation and nerve dam-
age (Ji et al., 1999, 2002; Karim et al., 2001; Ciruela et al., 2003;
Obata et al., 2003; Song et al., 2005). A variety of acute noxious
stimuli and chronic pain models result in ERK1/2 activation
(phosphorylation) at many levels of the nociceptive sensory sys-
tem including dorsal root ganglion (DRG), spinal cord, and
amygdala (Ji et al., 2009). The use of inhibitors that block activa-
tion of both ERK1 and ERK2 by inhibiting their shared upstream
MAP kinase kinases (MEK1/2) and transgenic expression in neu-
rons of a dominant-negative form of MEK1, which suppresses
MEK1/2–ERK1/2 signaling, have demonstrated that ERK1/2 is
necessary for nociceptive sensitization (Ji et al., 1999, 2002, 2009;
Karim et al., 2001, 2006; Song et al., 2005; Hu et al., 2006; Seino et
al., 2006).
Although much is known about MEK1/2–ERK1/2 signaling,
little is known about the specific functions of each ERK isoform.
Functional redundancy has been a working model because the
isoforms are 90% homologous (Boulton et al., 1991) and no
isoform-specific inhibitors currently exist. However, there is
emerging evidence that ERK1 and ERK2 may be functionally
distinct. ERK1 knock-outs (ERK1 KOs) are viable but exhibit
behavioral abnormalities correlated with altered synaptic plastic-
ity in striatum (Page`s et al., 1999; Selcher et al., 2001; Mazzucch-
elli et al., 2002), whereas ERK2 knock-outs are embryonic lethal
at embryonic day 8.5 (Krens et al., 2006). Alternativemethods for
targeting ERK2, including reduced expression from a hypomor-
phic mutant allele and conditional deletion in telencephalon,
have revealed a requirement for ERK2 in several learning and
memory paradigms (Satoh et al., 2007; Samuels et al., 2008). In
cell culture, genetic targeting or RNA interference (RNAi) exper-
iments suggest specific roles for ERK1 andERK2 (Mazzucchelli et
al., 2002; Vantaggiato et al., 2006). Evidence to support this hy-
pothesis includes the observations that ERK1 exclusively inter-
acts with the MEK–ERK signaling scaffold MP1 (Schaeffer et al.,
1998) and the fact that differences in amino acid sequence be-
tween ERK1 and ERK2 occur in domains thatmay affectMEK1/2
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binding, ERK dimerization, and subcellular localization (Boul-
ton et al., 1991; Zhang et al., 1994; Cobb and Goldsmith, 2000).
Indeed, ERK1 and ERK2 have different rates of shuttling between
the cytoplasm and nucleus because of sequence differences in the
N terminus (Marchi et al., 2008).
Currently, the importance of ERK1 in nociceptive sensitiza-
tion remains unknown. Therefore, we tested the necessity of
ERK1 in acute noxious sensitization and in models of chronic
inflammatory and neuropathic pain using ERK1 KO mice. Al-
though ERK1 is activated in these models, genetic deletion of
ERK1 had aminimal impact on these ERK-dependent behaviors.
Interestingly, ERK1 deletion increased basal ERK2 phosphoryla-
tion without affecting inflammation-induced changes in ERK2
phosphorylation. Our observations indicate that ERK1 is not re-
quired for nociceptive sensitization and suggest that ERK2 plays a
predominant role.
Materials andMethods
Animals. All experiments were performed according to the guidelines of
the National Institutes of Health and were approved by the Animal Care
andUse Committee ofWashingtonUniversity School ofMedicine.Mice
were housedwith a 12 h light/dark cycle and ad libitum access to food and
water. Targeted deletion of ERK1 was achieved by homologous recom-
bination in a process described in detail previously (Nekrasova et al.,
2005). Briefly, the targeting vector deleted exons 1–6 of mapk3, which
includes the kinase active site and phosphorylation loop, and replaced
them with a Neo cassette flanked with loxP sites. Embryonic stem cells
from 129 Sv mice were transfected and selected for homologous recom-
bination. Successfully targeted clones were injected into CD1 blastocysts,
which were implanted in pseudopregnant CD1 females. Chimeras with
germ-line transmission were obtained on the CD1 background. The
mapk3 mutation was subsequently transferred to the C57BL/6 back-
ground by backcrossing 10 times. C57BL/6 mapk3 mutant heterozy-
gotes were crossed, producing mice heterozygous for themapk3mutant
allele, homozygous for the mutant allele (ERK1 KO), and homozygous
for the wild-typemapk3 allele (WT). Seven- to 9-week-old ERK1KO and
WTmale littermates from these crosses were used in all experiments. The
experimenter was blind to the genotype and treatment in all behavioral
experiments.
Measurement of heat and mechanical thresholds. All behavioral tests
were performed in rooms isolated from other activity and with white
noise present. Tests were conducted at room temperature (25°C) dur-
ing the second half of the light cycle. Before testing, mice were allowed to
acclimate to the behavioral room and apparatus for 2–3 h. After acclima-
tion, measurements of paw withdrawal thresholds to heat and mechani-
cal stimuli were performed.Measurements were consistentlymade when
mice were calm. Modular clear Plexiglas behavior chambers (width, 10
cm; length, 10 cm; height, 15 cm), which could be placed on different
floor surfaces, were usedwith onemouse per chamber. Responses to heat
were measured using a modified Hargreaves test (Hargreaves et al.,
1988). Mice were placed in behavior chambers on a 390G Plantar Test
Apparatus (IITC Life Science) with a glass plate floor heated to 30°C.
Radiant heat was applied to the plantar surface of the hindpaw using a
focused beamof light with an active intensity of 14%maximal, a cutoff of
20 s, and idle intensity of 5%maximal. The 100% beam intensity heats to
250°C. To measure paw withdrawal latency, a timer was automatically
initiated at the onset of heat application (active intensity), and on paw
withdrawal, the heat source was returned to idle intensity automatically
stopping the timer. Five independent measurements, separated by 15
min alternating between right and left paws, were used to determine
baseline withdrawal latency. For time points hours after paw injections,
two independent measurements were averaged. On subsequent days,
three independent measurements were used. To measure responses to
mechanical stimuli, mice were placed in behavioral chambers on an ele-
vated wire mesh floor. Calibrated von Frey filaments (North Coast Med-
ical) were then applied through the mesh to the plantar surface of the
hindpaw between the anterior and posterior foot pads, except for the
spared nerve injury (SNI) experiment in which filaments were applied to
the lateral surface of the hindpaw in sural nerve territory. Filaments were
pressed into the skin until the filament bent, held for 1 s, and then
removed.Withdrawal of the hindpaw from themesh indicated a positive
withdrawal response. Each filament was applied five times at a frequency
of0.5 Hz. The lightest filament (0.008 g) was initially used followed by
progressively heavier filaments until the filament that evoked three with-
drawals out of five applications was reached. The calibrated force of the
filament was recorded as the paw withdrawal threshold. Three to five
independentmeasurements were averaged to yield the baseline threshold
for each hindpaw. Hours after paw injections, a single measurement was
used, whereas on subsequent days, three independent measurements
were averaged for each time point.
Formalin-induced spontaneous behaviors.Tomeasure spontaneous be-
havioral responses to formalin injection, mice were acclimated in behav-
ior chamberswith a Plexiglas floor for at least 1 h.Micewere then injected
subcutaneously with 10 l of 2% formalin (Sigma-Aldrich) in sterile
0.9% NaCl into the plantar surface of the hindpaw and immediately
returned to the behavior chamber. Total time spent licking and lifting
the injected paw was recorded in 5 min bins for 1 h. In experiments
with theMEK inhibitor,-[amino[(4-aminophenyl)thio]methylene]-2-
(trifluoromethyl)benzeneacetonitrile (SL327) (Tocris Bioscience), mice
were allowed to acclimate as above, injected with SL327 or vehicle
(DMSO), and then returned to the behavior chamber. Thirty minutes
later, mice were injected into the plantar surface of the hindpaw with
3.5% formalin, returned to the behavior chamber, and video recorded
frombelowwith awebcam (Logitech) at a resolution of 960 720 for 1 h
without the experimenter present. Subsequently, videos were scored for
time spent licking, lifting, and flinching the injected paw.
Formalin and complete Freund’s adjuvant-induced hypersensitivity.
Formalin-induced hypersensitivity to heat and mechanical stimuli was
used as a model of persistent pain. Heat hypersensitivity to formalin
was assayed by measuring baseline paw withdrawal latencies using a
Hargreaves-style apparatus as described above on day 1. On day 2, mice
were acclimated (2–3 h) and injectedwith 10l of 2% formalin (in sterile
0.9%NaCl). Thresholdmeasurements from the injected (ipsilateral) and
uninjected (contralateral) paws weremade at 1, 2, and 3 h after injection.
On subsequent postinjection days, mice were first allowed to acclimate
(2–3 h), and then pawwithdrawal thresholds were obtained. Tomeasure
mechanical hypersensitivity to formalin, a similar time course was per-
formed except von Frey filaments were used as detailed above. Intraplan-
tar injections of 10l of 3.5% formalin (in sterile 0.9%NaCl) weremade
and subsequent threshold measurements were obtained. A higher con-
centration of formalin was used in mechanical experiments because 2%
formalin did not produce robust mechanical hypersensitivity in either
WT or ERK1 KO mice (data not shown). Intraplantar injection of com-
plete Freund’s adjuvant (CFA) (10 l, 1.0 mg/ml; Sigma-Aldrich) was
used as a chronic inflammatory pain model. The same experimental
design used in formalin-induced hypersensitivity experiments was used
to assay mechanical and heat hypersensitivity after CFA injection.
Spared nerve injury model. To measure mechanical hypersensitivity
after spared nerve injury (Decosterd and Woolf, 2000), paw withdrawal
thresholds from the lateral surface of each hindpaw were obtained using
von Frey filaments with the up–down method (Chaplan et al., 1994).
Baseline thresholds weremeasured on day 1 after 2–3 h of acclimation on
wire mesh. On day 2, mice were anesthetized with pentobarbital, a small
incision in the thigh wasmade, and the threemain branches of the sciatic
nerve were exposed. The commonperoneal and tibial nerves were ligated
with 8-0 silk suture and cut distal to ligation. One millimeter of distal
nerve stumpwas removed, and the surgical woundwas closedwith 7mm
surgical clips. After 3 d of recovery, clips were removed. To measure
mechanical hypersensitivity after surgery, mice were acclimated to the
mesh (2–3 h), and mechanical withdrawal thresholds were measured
from the sural nerve territory (lateral surface of hindpaw).
Sample preparation and Western blot analysis. Mice were placed indi-
vidually in cages and allowed to acclimate for 2–3 h to approximate
behavioral testing conditions. For formalin and CFA experiments, mice
were then injected subcutaneously into the plantar surface of the hind-
paw with 10 l of 3.5% formalin or vehicle (0.9% NaCl) in formalin
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experiments or 10 l of CFA or 0.9% NaCl in CFA experiments. Mice
were then killed using a guillotine, and spinal cordswere rapidly removed
by hydraulic extrusion. In dose-finding experiments with SL327, mice
were acclimated as above, injected with SL327 or vehicle (DMSO), re-
turned to their cage for 30min, injected with 3.5% formalin, and killed 3
min after paw injection. Spinal cord levels lumbar 3–6 (L3–L6) were
isolated, and ipsilateral and contralateral sides were separated. For CFA
experiments, the dorsal half was isolated and flash-frozen on dry ice. For
formalin experiments, the entire dorsoventral extent was flash-frozen. In
experiments with uninjected mice, the lumbar enlargement was isolated
and flash-frozen without additional dissection. In naive subjects, imme-
diately after spinal cordextraction thoracic and lumbarDRGsweredissected
in ice-cold PBS (Mediatech), pooled into a single sample, and immediately
homogenized. Frozen spinal cord and fresh DRG samples were homoge-
nizedusingaDouncehomogenizer in ice-coldbuffer containing20mMTris,
pH7.5, 1mMEDTA,1mMNa4P2O7, 25g/ml aprotinin (Sigma-Aldrich),
25g/ml leupeptin (Sigma-Aldrich), 100M PMSF (Roche Applied Sci-
ence), 1 g/ml microcystin LR (Enzo Life Science), and 1 mM Na3VO4
(Sigma-Aldrich) in Milli-Q distilled water. Protein concentrations were
determined with the BCA protein assay (Pierce Biotechnology) and
SmartSpec 3000 spectrophotometer (Bio-Rad).
Protein homogenates were size separated by SDS-PAGE. For pERK/
ERK or ERK/actin Westerns, 10 g of protein was used. For c-Jun
N-terminal kinase (JNK) and p38 Westerns, 20 g of DRG homogenate
was used, and 20–40 g of spinal cord homogenate was used. For for-
malin and CFA experiments, precast Tris-HCl 4% stacking and 10%
separating polyacrylamide midi-gels were used (Bio-Rad). For experi-
ments with naive mice, 5% stacking and 10% separating polyacrylamide
mini-gels were prepared based on the Laemmli system (Coligan et al.,
2001). Gels were transferred to nitrocellulose membranes using a wet
transfer system (Bio-Rad). Membranes were blocked for 1 h at room
temperature (RT) with Odyssey blocking buffer (LI-COR Biosciences)
and then simultaneously probed with two primary antibodies from dif-
ferent host species for 1 h at RT diluted in blocking buffer unless other-
wise noted. Primary antibodies used include anti-pERK1/2 (mouse
monoclonal; 1:1000; Cell Signaling), anti-ERK1/2 (rabbit polyclonal;
1:1000; Cell Signaling), anti-actin (1:2000; mouse monoclonal; Sigma-
Aldrich), anti-JNK (rabbit polyclonal; 1:1000; Cell Signaling), anti-pJNK
(mousemonoclonal; 1:1000; Cell Signaling), anti-p38 (rabbit polyclonal;
1:1000; Cell Signaling), anti-p-p38 (mouse monoclonal; 1:500; primary
incubation for 4 h at RT; Cell Signaling), and anti--tubulin (mouse
monoclonal; 1:20,000; Sigma-Aldrich). After several washes,membranes
were then incubated for 1 h at RT with fluorescently conjugated second-
ary antibodies goat anti-rabbit IRDye800 (1:20,000; LI-COR Bio-
sciences) and goat anti-mouse Alexa Fluor 680 (1:20,000; Invitrogen),
which were detected with the Odyssey Infrared Fluorescence Imaging
System (LI-COR Biosciences) for simultaneous detection of 700 and 800
nm wavelength fluorescent emissions corresponding to mouse and rab-
bit primary antibodies, respectively. Densitometry of bands in 700
(pERK1/2, pJNK, p-p38, -tubulin, or actin) and 800 (ERK1/2, JNK,
p38) channels was performed using the Odyssey Infrared Fluorescence
Imaging System software (LI-COR Biosciences).
Immunohistochemistry. Mice were placed individually in cages and
allowed to acclimate for 2–3 h to approximate behavioral testing condi-
tions. Threeminutes after formalin injection (10l; 3.5% in 0.9%NaCl),
micewere overdosedwithAvertin anesthesia (1.25%working solution in
0.9% NaCl diluted from a stock of 1.0 mg/ml 2,2,2-tribromoethanol in
tert-amyl alcohol, both from Sigma-Aldrich) by intraperitoneal injec-
tion. Mice were then transcardially perfused at a rate of 15–20 ml per
minutewithwarm (37°C) PBS and then 150ml of ice-cold paraformal-
dehyde (4% in PBS). Spinal cord was isolated, rinsed in PBS overnight at
4°C, and then cryoprotected in 30% sucrose/PBS for 2 d at 4°C. Trans-
verse 30 m sections were obtained using a cryostat and collected in
ice-cold PBS. Floating sections were then stained for pERK1/2 using
3,3-diaminobenzidine (DAB) secondary detection. All incubationswere
performed with gentle agitation at RT, unless otherwise noted, with sev-
eral washes between steps. Endogenous peroxidase activity was sup-
pressed by incubating in 10%methanol, 0.3%H2O2 (in PBS) for 30min.
Sections were blocked with 1% normal goat serum/0.02% Triton X-100
in PBS (1%NGST) for 1 h, and then incubated in anti-pERK1/2 (1:3000
in 1%NGST; rabbit polyclonal; Cell Signaling) overnight at 4°C. Sections
were removed from 4°C and allowed to warm to RT for 1 h, after which
sections were incubated with biotinylated goat anti-rabbit IgG (1:200 in
1% NGST; Vector Laboratories) for 1 h and then extrAvidin peroxidase
(1:1000 in 1% NGST; Sigma-Aldrich) for 1 h. Finally, sections were in-
cubated for 6 min with a DAB solution supplemented with nickel pre-
pared from a DAB substrate kit (Vector Laboratories). Sections were
placed on microscope slides and dehydrated by exposing slices to etha-
nol/water solutions with progressively increasing concentrations of eth-
anol and finally CitriSolv (Thermo Fisher Scientific). After dehydration,
slides were coverslipped with distrene plasticizer xylenemountingmedia
(ElectronMicroscopy Sciences). Bright-field and dark-field images were
captured with a 10 objective using anOlympus compoundmicroscope
with a Photometrics CoolSnap HQ monochrome camera. Bright- and
dark-field images from the same field were then superimposed in Pho-
toshop (version 7.0; Adobe) and the lamina II–III boundary was traced
on the dark-field image. The boundary was then applied to the bright-field
image, and the resultant image was used to count positively staining cell
profiles in lamina I–II usingNIH ImageJ, version 1.42. During imaging and
quantification, the experimenter was blind to genotype. Color images were
obtained using a NanoZoomer automatedmicroscope (Hamamatsu).
Statistical analysis. Statistical analysis was performed using Excel (Mi-
crosoft) and Prism (GraphPad Software). Details of specific statistical
tests are included in Results. Graphs showing means and SEM were
graphed using Prism.
Results
Baseline sensory function remains normal in ERK1 KO mice
Although a large body of evidence indicates that ERK1/2 is im-
portant in nociception, little is known about the relative contri-
bution of each individual isoform. To assess the role of ERK1 in
nociceptive sensory function, we used mice with a targeted dele-
tion of mapk3 (ERK1 KO), in which part of exon 1 and all of
exons 2–6 are replacedwith a pPGKneolox cassette (Nekrasova et
al., 2005). Deletion of ERK1 was confirmed by Western blots of
spinal cord and DRG tissue obtained from ERK1 KO mice (Fig.
1A,B). As expected, ERK1 immunoreactivity was undetectable in
ERK1 KO mice (Fig. 1A,B) (unpaired t test, ***p  0.001). De-
letion of ERK1 had no effect on ERK2 protein expression (un-
paired t test). These data confirm previous findings that ERK1
protein is eliminated from the CNS (Selcher et al., 2001; Nekra-
sova et al., 2005) and extends these findings to the peripheral
nervous system by demonstrating ERK1 deletion without altered
ERK2 expression.
After confirming the absence of ERK1 in important nocicep-
tive anatomic loci, we measured the baseline sensory function of
ERK1 KO mice. The latency to paw withdrawal from a radiant
heat source was comparable between ERK1 KO and WT mice
(Fig. 1C). Additionally, pawwithdrawal thresholds tomechanical
stimulation with von Frey filaments in ERK1 KOmice were sim-
ilar to WT littermates (Fig. 1C). In both cases, there was no sta-
tistically significant difference between WT and ERK1 KO mice
(unpaired t test). Both sensory tests rely on reflexive withdrawal
of the hindlimb tomeasure threshold responses. Since alterations
in motor function secondary to ERK1 deletion could confound
the results of these tests, we also screened the ERK1 KOmice for
motor abnormalities.We foundnodifference in the performance
of ERK1 KO and WTmice on the accelerating rotarod task or in
exploratory behaviors in an open-field task (supplemental Fig.
S1, available at www.jneurosci.org as supplemental material).
Overall, these results indicate that genetic disruption of ERK1
does not affect baseline withdrawal responses from heat or me-
chanical stimuli.
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ERK1 is not required for first or second phases of the
formalin test
Previous reports indicate that spinal ERK1 is activated (phos-
phorylated) within minutes after intraplantar injection of the
noxious chemical formalin and that inhibition of spinal ERK1/2
using intrathecally applied MEK inhibitors reduces the second
phase of spontaneous formalin-inducednociceptive behaviors (Ji
et al., 1999; Karim et al., 2001). Therefore, we hypothesized that
ERK1 was necessary for full expression of spontaneous nocicep-
tive behaviors after formalin injection. Surprisingly, ERK1 KO
and WT littermates have indistinguishable formalin responses
(Fig. 2). Both WT and ERK1 KO show a stereotypical biphasic
response characterized by an immediate increase in licking and
lifting (first phase), which subsides momentarily but gradually
increases and persists over the after 30 min (second phase).
There is no statistically significant difference between genotypes
when considering the complete time course of the formalin re-
sponse [two-way repeated-measures (RM) ANOVA: F  0.64,
DFn 1, DFd 308, p 0.4304].Moreover, the amount of time
spent in nociceptive behaviors in the first phase (0–5 min) and
the second phase (5–40 min) is similar between the genotypes
(Fig. 2, unpaired t test). Overall, these data indicate that, even in
the absence of ERK1, formalin can induce robust spontaneous
behaviors that have previously been shown to require ERK1
and/or ERK2, suggesting a specific role for ERK2 in this process.
ERK1 KOmice develop robust hypersensitivity in long-term
inflammatory and neuropathic pain models
ERK1 and/or ERK2 contribute to the development and mainte-
nance of chronic inflammatory and neuropathic pain (Ji et al.,
2009). To directly assess the contribution of ERK1 fromall tissues
to CFA-induced hypersensitivity, ERK1 KO mice were injected
with CFA into the hindpaw and examined for hypersensitivity to
radiant heat and mechanical stimuli over time. ERK1 KO mice
became robustly hypersensitive to radiant heat applied to the
paw ipsilateral to CFA injection (Fig. 3A). The degree of hy-
persensitivity in ERK1 KO mice was comparable with WT lit-
termate controls (two-way RM ANOVA: F  1.38, DFn  1,
DFd  90, p  0.2562). In the contralateral paw, there was no
statistically significant hypersensitivity over time (two-way RM
ANOVA: F 1.96, DFn 5, DFd 90, p 0.0923). Moreover,
there was no statistically significant difference between the geno-
types (two-way RMANOVA: F 2.26, DFn 1, DFd 90, p
0.1504). CFA injection also produced dramatic hypersensitivity
to mechanical stimulation that was indistinguishable between
WT and ERK1KO littermates (Fig. 3B). There was no statistically
significant difference between genotypes in withdrawal thresh-
olds in the ipsilateral paw (two-way RM ANOVA: F  0.86,
Figure 1. Disruption of mapk3 eliminates ERK1 expression in spinal cord and dorsal root
ganglionwithout affectingheat or light touch thresholds.A, Spinal cordswere isolated fromWT
(n 13) and ERK1 KO (n 14) littermates and analyzed by Western blot for ERK1/2 and the
loading control, actin. To quantify the intensity of ERK bands, integrated intensities of each
isoform were divided by actin integrated intensities and plotted as fold WT. B, DRGs from WT
(n 7) and ERK1 KO (n 8)were dissected and analyzed by quantitativeWestern blot as inA.
In both spinal cord and DRGs, there is a dramatic reduction in ERK1 expressionwithout a signif-
icant change in ERK2protein levels.C, Nodifferenceswereobserved inheat thresholds obtained
by applying radiant heat to the hindpaws of WT (n 10) and ERK1 KO (n 10) littermates
usingaHargreaves-style apparatus.Nodifferenceswereobserved inhindpawmechanicalwith-
drawal thresholds obtained with von Frey filaments fromWT (n 14) and ERK1 KO (n 13)
littermates. Error bars indicate SEM. ***p 0.001, unpaired t test.
Figure 2. Formalin-induced spontaneous nociceptive responses are preserved in ERK1 KO
mice. The amount of time spent in spontaneous nociceptive behaviors after 2% formalin injec-
tion (licking and lifting of the injected paw)was recorded fromWT (n 16) and ERK1 KO (n
14) littermates and plotted in 5min bins. No statistically significant difference betweenWT and
ERK1 KOwas detected over the course of the 60min trial or in total time spent in the first phase
(0–5 min, bottom left graph) or second phase (5–40 min, bottom right graph) of nociceptive
behaviors. Error bars represent SEM.
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DFn 1, DFd 70, p 0.3761) or the contralateral paw (two-
way RM ANOVA: F  4.41, DFn  1, DFd  70, p  0.062).
Overall, these data indicate that ERK1 KO mice show normal
sensitization to mechanical and heat stimuli in the CFAmodel of
long-term inflammatory pain.
The mechanisms driving nociceptive sensitization in neuro-
pathic pain are often distinct from inflammatory pain. Indeed,
the time course and anatomic localization of ERK1/2 phosphor-
ylation is different between neuropathic (Obata et al., 2004;
Zhuang et al., 2005) and inflammatory (Ji et al., 2002;Obata et al.,
2003) painmodels. However, the relative importance of ERK1 or
ERK2 in neuropathic pain remains unknown. To address this
issue, we measured the responses of ERK1 KO mice in the SNI
model, in which two branches of the sciatic nerve are transected
(tibial and common peroneal branches), leaving the third
branch, the sural nerve, intact. In skin innervated by the sural
nerve ipsilateral to SNI, ERK1KOandWTmice developed equiv-
alent, robust mechanical hypersensitivity (Fig. 4). In the con-
tralateral paw, withdrawal thresholds remained unchanged
relative to baseline. There is no statistically significant difference
between ERK1 KO andWT littermates in withdrawal thresholds
ipsilateral (two-way RM ANOVA: F  0.05, DFn  1, DFd 
102, p  0.8263) or contralateral (two-way RM ANOVA: F 
0.89, DFn 1, DFd 102, p 0.3591) to the nerve injury. These
results indicate that ERK1 KO mice are equally susceptible to
SNI-induced mechanical hypersensitivity as WT littermates,
suggesting that ERK1 is not required in this model of neuro-
pathic pain.
ERK1 KOmice show reduced heat hypersensitivity after
intraplantar injection of formalin
Intraplantar injection of formalin produces well characterized
immediate spontaneous behaviors, which give way to hypersen-
sitivity to heat and mechanical stimuli hours after the injection
(Fu et al., 2001; Zeitz et al., 2004; Hu et al., 2006). Inhibition of
ERK1/2 activation in the amygdala has no effect on immediate
spontaneous behaviors but, instead, dramatically reduces
long-term formalin-induced hypersensitivity (Carrasquillo
and Gereau, 2007). Therefore, we reasoned that, although there
was no apparent role of ERK1 in formalin-induced spontaneous
nociceptive behaviors, ERK1 may be involved in longer-term
formalin-induced hypersensitivity. To test this hypothesis, we
injected ERK1 KO and WT littermates with formalin and mea-
sured responses to heat and mechanical stimuli. Interestingly,
ERK1KOmice showed attenuated heat hypersensitivity 1 and 2 h
after 2% formalin injection in the ipsilateral paw (Fig. 5A). A
two-way repeated-measures ANOVA confirmed this difference,
indicating a significant main effect of genotype (F 9.69; DFn
1; DFd 56; p 0.0076) with a Bonferroni post test revealing a
significant difference at 1 and 2 h time points ( p 0.05). Neither
WT nor ERK1 KO mice developed heat hypersensitivity in the
contralateral paw. At the same time points after 3.5% formalin
injection, ERK1 KO mice developed robust mechanical hyper-
sensitivity ipsilateral to injection that was similar to WT litter-
mates (Fig. 5B). Although 1 and 3h timepoints appear elevated in
ERK1 KO mice, there is no statistically significant difference be-
tween the genotypes (two-way RM ANOVA: F 3.81, DFn 1,
DFn 60, p 0.0700). It is important to note that we used 3.5%
formalin to measure mechanical hypersensitivity. In WT mice
obtained from ERK1 heterozygous crosses, 2% formalin did not
produce robust mechanical hypersensitivity (data not shown).
Using 2% formalin, we observed no difference between ERK1KO
andWT littermates (data not shown).Overall, these data indicate
that ERK1 KO mice do not fully express formalin-induced heat
hypersensitivity, despite normal formalin-induced mechanical
hypersensitivity.
Deletion of ERK1 elevates ERK2 phosphorylation without
affecting ERK2 expression
ERK1 and ERK2 are both phosphorylated byMEK1/2, giving rise
to the possibility that eliminating one ERK isoform might alter
the phosphorylation state of the remaining isoform. The effect of
Figure 3. ERK1 is not necessary for CFA-induced hypersensitivity. A, To measure CFA-
induced heat hypersensitivity, WT (n 10) and ERK1 KO (n 10) littermates were injected
with CFA subcutaneously into the plantar surface of the hindpaw. Pawwithdrawal latencies to
a radiant heat stimuluswere thenobtained frombothhindpaws, ipsilateral and contralateral to
CFA injection, using a Hargreaves-style apparatus. Data were normalized to preinjection base-
line pawwithdrawal latencieswithin subject andplotted as percentagebaseline.B, Tomeasure
CFA-inducedmechanical allodynia, WT (n 6) and ERK1 KO (n 6) littermates were injected
with CFA, and paw withdrawal thresholds to light touch were measured using von Frey fila-
ments. In all cases, there was no statistically significant difference between genotypes. Error
bars indicate SEM.
Figure 4. ERK1 KO and WT littermates develop similar mechanical hypersensitivity after
peripheral nerve injury. One day after baseline measurements, WT (n 9) and ERK1 KO (n
10) littermates were anesthetized, and the tibial and common peroneal branches of the sciatic
nervewere ligated then transected, leaving the sural branch intact. After the sparednerve injury
surgery, paw mechanical withdrawal thresholds were measured ipsilateral (solid lines) and
contralateral (dashed lines) tonerve injury. Baselineandpostinjurywithdrawal thresholdswere
determined by probing the lateral plantar surface of the paw, which is innervated by the sural
nerve. Data are representedaspercentagebaselinewithin each subject. Error bars indicate SEM.
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ERK1 deletion on ERK2 phosphorylation in spinal cord or DRG
remains unknown. Therefore, we analyzed tissue from naiveWT
and ERK1 KOmice byWestern blot to size separate the isoforms
and quantify the basal phosphorylation state of each isoform in-
dependently (Fig. 6A). Interestingly, ERK1 KOmice have signif-
icantly elevated basal ERK2 phosphorylation compared withWT
littermates in both spinal cord and DRG. It is important to note
that, in these tissues, total ERK2 expression remains unaltered
(Fig. 1). To determine whether the activity of structurally related
MAP kinases may be affected by ERK1 deletion, we analyzed
spinal cord andDRGhomogenates fromnaiveWTandERK1KO
littermates for JNK and p38 expression and phosphorylation
(Fig. 6B–D). No significant difference was detected between
ERK1 KO and WT homogenates, suggesting that altered basal
p38 or JNK activity cannot account for the minimal behavioral
impact of ERK1 deletion. Overall, these data do indicate that, in
spinal cord and DRG, ERK1 elimination results in enhanced
basal phosphorylation of ERK2.
Inflammation-induced elevation of pERK2 is equivalent
between ERK1 KO andWT littermates
Given that ERK2 phosphorylation is elevated in naive ERK1 KO
mice, we hypothesized that noxious stimulation would lead to
hyperphosphorylation of ERK2. To test this hypothesis, ERK1
KO andWTmice were injected with either formalin or saline and
killed at the peak of formalin-induced ERK1/2 phosphorylation
in spinal cord (3min after injection) (Fig. 7A). After normalizing
to the total ERK loading control, ipsilateral intensities were di-
vided by contralateral intensities within each subject, to provide a
within-animal control. As previously reported (Karim et al.,
2001), injection ofWTmicewith formalin significantly increased
pERK1 and pERK2 compared withWT saline-injectedmice (Fig.
7A) (for pERK1: unpaired t test, p 0.001; for pERK2: two-way
ANOVA, F 55.92, DFn 1, DFd 20, p 0.0001). ERK1 KO
mice also show significant elevation of pERK2 after formalin in-
jection (two-way ANOVA: F 55.92, DFn 1, DFd 20, p
0.0001). Interestingly, there is no significant difference between
WT and ERK1 KO littermates in formalin-induced pERK2 in-
creases (two-way ANOVA: F  2.11, DFn  1, DFd  20, p 
0.1617). These data suggest that ERK1 deletion does not affect the
change in spinal ERK2 phosphorylation attributable to formalin-
induced inflammation. Similar results were obtained when using
the CFA model of inflammation (Fig. 7B). WT and ERK1 KO
littermates were injected with CFA or saline and killed at the peak
time point of CFA-induced ERK1/2 phosphorylation (30 min
after injection) (Ji et al., 2002).Western blot analysis of the dorsal
portion of L3–L6 spinal cords indicated a significant increase in
ipsilateral pERK1 forWT and pERK2 for bothWT and ERK1KO
mice injected with CFA compared with saline-injected mice
(pERK1: unpaired t test, p  0.001; pERK2: two-way ANOVA,
F 21.02, DFn 1, DFd 17, p 0.0003). This CFA-induced
increase in pERK2 was not different between WT and ERK1 KO
mice (two-way ANOVA: F  0.13, DFn  1, DFd  17, p 
0.7202). Similar resultswere obtained bynormalizing pERK/ERK
values toWT saline (supplemental Figs. S2, S3, available at www.
jneurosci.org as supplemental material). Using this alternative
analysis, ERK1 KO mice have elevated pERK2 in all conditions
compared withWT littermates. However, the relative increase in
pERK2 attributable to formalin or CFA appears similar between
WT and ERK1 KO, as is reflected in Figure 7. Overall, these data
indicate that ERK1 deletion does not affect inflammation-
induced elevation of pERK2.
Formalin-induced pERK1/2 immunostaining is slightly
reduced in ERK1 KO mice
Although increases in pERK2 after noxious stimulation appear
unaffected by ERK1 deletion, it is possible that the anatomic
localization of pERK2 is altered which may reflect compensatory
changes in nociceptive circuitry arising from the loss of ERK1
during development. To address this, ERK phosphorylation was
measured by immunohistochemistry with a phosphospecific
ERK1/2 antibody, since current antibodies cannot discriminate
between pERK1 and pERK2 because of high sequence homology
in the phosphorylation loop. ERK1 KO mice were injected with
formalin and L3–L4 spinal cord sections were stained for
pERK1/2. Interestingly, formalin-injected ERK1 KO mice had a
similar pattern of pERK1/2 immunoreactivity to WT littermates
(Fig. 8A). For both genotypes, positively staining cell profiles and
more diffuse fiber staining was evident in the superficial lamina
of the dorsal horn ipsilateral to paw injection. The dorsoventral
or mediolateral extent of pERK1/2 immunostaining was not ap-
preciably different between genotypes. To quantify pERK1/2
staining, all pERK1/2-positive cell profiles found in the superfi-
cial dorsal horn (lamina I and lamina II), as defined by dark-field
illumination, were counted from serial sections separated by at
least 90 m (Fig. 8B). In both WT and ERK1 KO littermates,
significantly more pERK1/2-positive cell profiles appear ipsilat-
eral to formalin injection than contralateral (two-way ANOVA:
F  56.68, DFn  1, DFd  4, p  0.0017). Interestingly, the
number of pERK1/2-positive cell profiles ipsilateral to formalin
injection is significantly reduced in ERK1 KO mice compared
Figure 5. ERK1 contributes to the onset of heat hypersensitivity after intraplantar formalin
injection.A, To assess the role of ERK1 in long-term formalin-induced heat hypersensitivity,WT
(n 8) and ERK1 KO (n 8) littermates were injected with 2% formalin subcutaneously into
the plantar side of the right hindpaw. Paw withdrawal latencies were measured before and
after injection and are graphed as percentage of preinjection baseline. ERK1 KO mice have
reduced hypersensitivity to heat at 1 and 2 h after formalin injection in the ipsilateral paw
(two-way RM ANOVAwith Bonferroni’s post test, *p 0.05). B, Tomeasure formalin-induced
mechanical hypersensitivity, WT (n 8) and ERK1 KO (n 9) littermates were injected with
3.5% formalin. Pawwithdrawal thresholdswere obtainedusing von Frey filaments. Therewere
no statistically significant differences betweenWT and ERK1 KO. Error bars reflect SEM.
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with WT littermates (two-way ANOVA: F  9.79, DFn  1,
DFd 8, p 0.0141). This likely reflects the loss of ERK1 phos-
phorylation after formalin, which is normally seen in WT mice
(Fig. 7). Importantly, in ERK1 KO mice formalin-induced
pERK1/2 immunostaining is not elevated and does not occur in
unexpected laminae of the dorsal horn. Both observations would
argue against the potential confounds of ERK2 hyperphosphory-
lation or developmental remodeling of nociceptive circuitry.
MEK inhibition attenuates formalin-induced spontaneous
behaviors similarly inWT and ERK1 KO littermates
Although we observed no change in p38 or JNK expression or
phosphorylation with ERK1 deletion, it remains possible that
other signaling pathways compensate for the loss of ERK1 in the
context of nociceptive sensitization. To address this possibility,
we sought to test whetherMEK inhibition
could reduce formalin-induced sponta-
neous nociceptive behaviors in ERK1 KO
mice, as has been reported in WT mice
(Karim et al., 2001). Previous studies have
used intrathecal delivery of MEK inhibi-
tors. Since ERK1 is eliminated in all tissues
of the ERK1KO and since ERK1/2 activity
is important for nociceptive sensitization
in areas in addition to spinal cord, a more
appropriate test would involve systemic
MEK inhibition. SL327 is a structural an-
alog of U0126 [1,4-diamino-2,3-dicyano-
1,4-bis(2-aminophenylthio)butadiene]
that is blood-brain barrier permeable and
has previously been used to inhibit MEK
in the brain by systemic intraperitoneal
administration (Atkins et al., 1998). How-
ever, it has not yet been used in the formalin
test and has not been evaluated in spinal
cord. Thus, we began our study by deter-
mining the dose of SL327 required to max-
imally inhibit formalin-induced ERK1/2
phosphorylation in spinal cord (Fig. 9A).
Pretreatment with both 30 and 50 mg/kg
SL327 intraperitoneally 30 min before
3.5% formalin injection to the hindpaw
significantly reduced pERK1 and pERK2
in spinal cord tissue ipsilateral and con-
tralateral to the injected paw (one-way
ANOVA: pERK1 ipsi, F 14.9, DFn 3,
DFd  11, p  0.0012; pERK2 ipsi, F 
29.85, DFn  3, DFd  11, p  0.0001;
pERK1 contra, F  15.23, DFn  3,
DFd 11, p 0011; pERK2 contra, F
36.42, DFn  3, DFd  11, p  0.0001).
Therefore, we used 50 mg/kg SL327 to
evaluate the effect of systemic MEK inhi-
bition on the formalin test in both WT
and ERK1KO littermates (Fig. 9B). SL327
at 50 mg/kg significantly attenuated for-
malin-induced spontaneous nociceptive
behaviors in WT mice (two-way RM
ANOVA: F 8.09, DFn 1, DFd 198,
p  0.0108). Importantly, no difference
was detected between WT and ERK1 KO
mice injected with SL327 (two-way RM
ANOVA: F 0.91, DFn 1, DFd 187,
p 0.3528). Vehicle-injected ERK1 KO andWT littermates also
behaved similarly (two-way RM ANOVA: F  0.08, DFn  1,
DFd 165, p 0.7795), recapitulating results from Figure 2 in
animals injected with DMSO. Overall, these data indicate that
systemicMEK inhibition reduces spontaneousnociceptive behavior
in the formalin test regardless of ERK1 deletion, suggesting that
compensation fromMEK-independent signaling pathways inERK1
KO is negligible.
Discussion
Although it is clear that ERK1 and/or ERK2 drive behavioral
sensitization in many pain models, little is known about the rel-
ative contribution of each isoform and whether they are redun-
dant. This study is the first to address directly the role of ERK1 in
rodent models of pain by characterizing the nociceptive function
Figure6. In spinal cord andDRG, basal ERK2phosphorylation increases in the absenceof ERK1.A, Spinal cord (SC) homogenates
from naive WT (n 7) and ERK1 KO (n 8) littermates were analyzed simultaneously for pERK1/2 and ERK1/2 by quantitative
Western blot. Although there is no difference in total ERK2 expression in ERK1 KO spinal cord (Fig. 1), ERK2 phosphorylation is
significantly elevated. Similar results were observed in whole-cell homogenates prepared from DRG (WT, n 7; ERK1 KO, n 8;
unpaired t test, *p  0.05). B–D, The same spinal cord and DRG homogenates were used to evaluate the expression and
phosphorylation of related MAPKs, JNK and p38. The integrated intensities of JNK2/3, JNK1, and p38 bands were divided by
corresponding loading control -tubulin bands, normalized to the mean WT intensity, and expressed as fold WT. To evaluate
phosphorylation, pJNK2/3, pJNK1, and p-p38 bands were divided by their corresponding total protein bands from the same
samples, normalized, and then expressed as fold WT. No significant difference was detected between WT and ERK1 KO mice in
either spinal cord or DRG (WT SC, n 7; ERK1 KO SC, n 8; WT DRG, n 5; ERK1 KO DRG, n 6; unpaired t test). WT data are
represented with white bars, and ERK1 KO data are represented with gray bars. Error bars indicate SEM.
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of ERK1 KO mice. We found that acute
sensitivity tobothnoxiousheatandthenox-
ious chemical, formalin, remains intact de-
spite the loss of ERK1 fromall tissues. ERK1
deletion does not affect hypersensitivity at-
tributable to chronic inflammationornerve
injury. Interestingly, long-term formalin-
induced hypersensitivity to heat is slightly
reduced by ERK1 deletion. Together, these
data suggest ERK1 is not required for noci-
ceptive sensitization.
Accumulating evidence from this study
and elsewhere strongly suggests that spinal
ERK2, and not ERK1, is critical for CFA-
induced hypersensitivity. Targeting ERK1/2
nonspecifically with intrathecally applied
MEK inhibitors attenuates CFA-induced
hypersensitivity (Ji et al., 2002; Obata
et al., 2003). Interestingly, RNAi-mediated
ERK2 knockdown in spinal cord dra-
matically reduces CFA-induced behav-
ioral sensitization (Xu et al., 2008).
However, because of the partial reduction
of ERK2 expression achieved with this
method, there was a relatively small effect
on ERK2 phosphorylation. ERK2 knock-
down also caused an elevation of ERK1
phosphorylation in the spinal cord. In the
physiologically normal context of isoform
coexpression, spinal ERK1 is phosphory-
lated after CFA injection to the paw (Ji et
al., 2002; Obata et al., 2003; Adwanikar et
al., 2004; Xu et al., 2008), raising the pos-
sibility that ERK1 plays some role in be-
havioral sensitization. The current study
directly addresses this question anddemon-
strates that ERK1 deletion has no effect on
CFA-inducedheat ormechanical hypersen-
sitivity. Given the combined results of tar-
geting MEK, ERK2, and now ERK1, it is
likely that spinal ERK2 specifically drives
CFA-induced hypersensitivity.
In the present study, we observed that ERK1 deletion is ac-
companied by increased ERK2 phosphorylation in the spinal
cord and DRG of naive mice. This could arise if ERK isoforms
normally compete for binding and phosphorylation with their
shared upstream kinase MEK. Without ERK1 expression, MEK
binds and exclusively phosphorylates the remaining isoform
ERK2. Similar observations have been made in other systems,
supporting such a model of MEK–ERK1/2 interaction. In NIH/
3T3 cells, RNAi-mediated knockdownof one isoformelevates the
phosphorylation state of the remaining isoform (Vantaggiato et
al., 2006; Lefloch et al., 2008). However, the degree of isoform
competition varies with context. In vivo, ERK1 deletion only af-
fects ERK2 phosphorylation in certain non-neuronal tissues,
such as the thymus (Nekrasova et al., 2005), but not in hippocam-
pus, cortex, and striatum (Mazzucchelli et al., 2002). However,
primary cultures of cortex or striatum from ERK1 KO embryos
exhibit ERK2 hyperphosphorylation after stimulationwith either
glutamate or KCl without altered phosphorylation in untreated
cultures. It appears that MEK–ERK1/2 interactions depend on
cellular context, relative activity ofMEK–ERK signaling, and per-
haps developmental context given the differences between em-
bryonic cultures and adult mice (Mazzucchelli et al., 2002).
In all studies using isoform-specific knock-out or knock-
down, the functional importance of ERK isoformhyperphospho-
rylation is difficult to separate from the effect of deleting the
targeted isoform. In ERK1 KO mice, ERK2 hyperphosphoryla-
tion in striatal cultures is correlated with augmented long-term
synaptic potentiation in striatum and enhanced place preference
conditioning for morphine (Mazzucchelli et al., 2002). Similar
ERK2 hyperphosphorylation occurs in hippocampal cultures
from ERK1 KO embryos (Mazzucchelli et al., 2002), but there is
minimal impact of ERK1 deletion on hippocampal plasticity and,
behaviorally, no effect on hippocampus-dependent tasks such as
contextual fear conditioning and passive avoidance (Selcher et
al., 2001). In the present study, elevated ERK2 phosphorylation is
not associated with altered baseline withdrawal responses to nox-
ious heat or mechanical stimulation, and there is no gain-of-
function in nociceptive sensitization. Additionally, spinal pERK2
elevation above baseline after intraplantar formalin or CFA is
similar between WT and ERK1 KO. This suggests that elevated
basal ERK2 phosphorylation is unrelated to nociceptive sensiti-
Figure 7. Inflammation-induced ERK2 phosphorylation is not elevated in ERK1 KO mice. A, ERK1 KO and WT littermates were
injected subcutaneously into the plantar surface of the hindpaw with saline or 3.5% formalin (n 6 per group) and killed 3 min
later. The dorsoventral extent of L3–L6 spinal cord was isolated and processed for pERK1/2 and ERK1/2 quantitativeWestern blot
analysis. Ipsilateral pERK/ERK intensities were normalized to contralateral intensities from the same subject, and data were
graphed as fold contralateral. Formalin injection led to significantly elevated pERK1 and pERK2 in WT mice. In ERK1 KO mice, the
formalin-induced increase in pERK2 was similar to WT. B, ERK1 KO and WT littermates were injected subcutaneously into the
plantar surface of the hindpawwith saline or CFA (n 5–6 per group). After 30min, the dorsal halves of L3–L6 spinal cordswere
obtained and analyzed for pERK1/2 and ERK1/2 by Western blot as above. As with formalin injection, CFA-injected WT mice had
significantly elevated pERK1 and pERK2. Elimination of ERK1 had no significant impact on CFA-induced pERK2 elevation. Error bars
represent SEM. Unpaired t test or two-way ANOVA with Bonferroni’s post test: *p 0.05, **p 0.01, ***p 0.001.
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zation. Basal phosphorylationmay occur in non-nociceptive cells
of the spinal cord, or it may be an artifact of tissue preparation or
homogenization. In both cases, deletion of ERK1 would lead to
ERK2 hyperphosphorylation only in this non-nociceptive-
specific pool of ERK.
An alternative interpretation is that ERK2 hyperphosphoryla-
tion actually relates to nociception and functionally compensates
for the loss of ERK1, masking a physiologic role for ERK1.We do
not favor this interpretation for several reasons. First, knock-
down of spinal ERK2 also increases basal ERK1 phosphorylation
without affecting baseline sensory responses but with a profound
effect on CFA-induced hypersensitivity (Xu et al., 2008). If ERK
isoforms were interchangeable in the nociceptive spinal cord,
then one would expect ERK1 to compensate for the loss of ERK2,
which did not occur. Second, pERK1/2 immunohistochemistry is
actually reduced in ERK1 KO mice, indicating that elevated
pERK2 cannot make up for the loss of ERK1 in total pERK1/2
immunoreactivity. If isoforms were completely redundant, this
net loss of pERK1/2 would be expected to affect formalin-
induced spontaneous behaviors.Nevertheless, it remains difficult
to exclude a role for ERK1 without directly testing ERK2 func-
tion. The converse is also true, and, as such, the current study
solidifies our understanding of spinal ERK2 function in the CFA
model, as outlined above.
To our knowledge, the present study is the first to examine the
role of ERK isoforms in the formalin model of chemical nocicep-
tion. Moreover, our experiments with the systemically active
MEK inhibitor, SL327, provide additional evidence that ERK1/2
activity is required for the behavioral response to formalin. Since
Figure 8. Noxious peripheral stimulation induces pERK1/2 immunoreactivity in superficial
dorsal horn laminae despite the loss of ERK1. A, Threeminutes after subcutaneous intraplantar
injection of 3.5% formalin, WT and ERK1 KO littermates were killed and analyzed for pERK1/2
immunoreactivity in lumbar spinal cord. On the side of the spinal cord ipsilateral to paw injec-
tion, pERK1/2-positive cell profiles appear in the superficial lamina of formalin-injectedWT and
ERK1 KOmice. Diffuse staining is also apparent, possibly because of ERK1/2 phosphorylation in
dendrites or afferent fibers. In bothWTandERK1KO, there is nogross difference in the anatomic
pattern of pERK1/2 staining. B, To quantify results from A, pERK1/2-positive cell profiles in
laminae I–IIwere counted from six sections per animalwith three animals per group. Themean
number of cell profiles for each subject was then used to calculate the mean number for the
entire group. Formalin stimulation significantly increases pERK1/2-positive cell profiles in both
WT and ERK1 KO littermates. Two-way ANOVA with Bonferroni’s post test: *p 0.05, **p
0.01. Error bars reflect SEM.
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Figure 9. Systemic MEK inhibition attenuates formalin-induced spontaneous behaviors
similarly inWT and ERK1 KO littermates. A, Several doses of the blood–brain barrier-permeant
MEK inhibitor, SL327, or vehicle (DMSO) were administered intraperitoneally 30 min before
hindpaw intraplantar formalin injection (3.5% in saline). Subjects (n 3 per dose) were killed
3 min after formalin injection, and homogenates of spinal cord tissue ipsilateral and contralat-
eral to the paw injection were analyzed for ERK phosphorylation. SL327 significantly reduced
pERK1/ERK1 and pERK2/ERK2 at 30 and 50 mg/kg [one-way ANOVA with Dunnett’s post test
comparing to vehicle (0) within ERK isoform; **p 0.01, ***p 0.001]. B, ERK1 KO and WT
mice were injected with either vehicle (1 ml/kg DMSO) or 50 mg/kg SL327 intraperitoneally
(WT–vehicle, n 9;WT–SL327, n 11; KO–vehicle, n 8; KO–SL327, n 8). After 30min,
formalin (3.5% in saline) was injected subcutaneously into the plantar surface of the hindpaw,
and spontaneous nociceptive behaviors were measured. SL327 significantly attenuated
formalin-induced nociceptive behaviors in both WT and ERK1 KO littermates (two-way RM
ANOVA with Bonferroni’s post test; asterisks comparing WT–vehicle and WT–SL327, **p
0.01, ***p 0.001; daggers comparing KO–vehicle and KO–SL327, ††p 0.01). No signifi-
cant difference was detected betweenWT and ERK1 KOmice injected with SL327.
Alter et al. • ERK1 in Pain Models J. Neurosci., August 25, 2010 • 30(34):11537–11547 • 11545
SL327 exerts similar effects in WT and ERK1 KO mice, it seems
likely that ERK2 is specifically required in this behavioral model,
although this must be directly tested. It is tempting to hypothe-
size that the underlying cellular mechanisms of the formalin test
would also rely on ERK2 and not ERK1. These mechanisms may
include sensitization processes in spinal cord that amplify incom-
ing nociceptive information via enhanced synaptic strength and
intrinsic excitability (Ikeda et al., 2006; Sandku¨hler, 2009), both
of which involve ERK1/2 (Ji et al., 2009). Formalin also increases
primary afferent activity, which likely contributes to immediate,
phase 1 behavioral responses (Puig and Sorkin, 1996). Since SL327
decreases the first phase of the formalin test and since ERK1 appears
to be dispensable for formalin-induced spontaneous behaviors,
our results predict that ERK2 specifically contributes to elevated
afferent activity, perhaps by increasing excitability via direct phos-
phorylation of voltage-gated sodium channels (Stamboulian et al.,
2010).
Noxious stimulation or inflammation induces hypersensitivity
to heat, which is primarily attributable to peripheral sensitization of
primary afferent nociceptors (Levine and Alessandri-Haber, 2007).
Previous studies have demonstrated a role for nociceptor ERK1/2 in
inflammation-induced peripheral sensitization using MEK in-
hibitors (Dai et al., 2002; Obata et al., 2003; Zhuang et al., 2004;
Seino et al., 2006). ERK1/2 may contribute to heat hypersensitiv-
ity by modulating TRPV1 (Zhuang et al., 2004; Firner et al.,
2006), which is a molecular sensor of noxious heat that is re-
quired for CFA-induced heat hypersensitivity (Caterina et al.,
2000; Levine and Alessandri-Haber, 2007). Our observation that
ERK1 is not required for CFA-induced heat hypersensitivity sug-
gests that ERK2 may specifically modulate TRPV1, a possibility
thatmust be directly tested. Interestingly, our results also indicate
that formalin-induced heat hypersensitivity is in part mediated
by ERK1. The discrepancy between CFA- and formalin-induced
heat hypersensitivity reported here may be the result of dis-
crete parallel signaling pathways within nociceptive terminals
that are sensitive to either CFA or formalin. Given that ERK1
KOmice develop heat hypersensitivity at later time points after
formalin injection, it is also possible that ERK1 contributes to
heat hypersensitivity but ultimately ERK2 is sufficient to induce
sensitization.
In addition to spinal cord and DRG, ERK1/2 is activated in
many regions of the nociceptive system after noxious stimulation
including the amygdala (Carrasquillo and Gereau, 2007). In
amygdala,microinjection ofMEK inhibitors does not affect acute
formalin-induced spontaneous behaviors but does attenuateme-
chanical hypersensitivity. In the current study, we found that
ERK1 deletion does not affect formalin-induced mechanical hy-
persensitivity. This fits well with our previous observations that
formalin did not significantly induce ERK1 phosphorylation in
amygdala (Carrasquillo and Gereau, 2007). However, since
amygdala MEK inhibition affected both ERK1 and ERK2 phos-
phorylation, it was difficult exclude a role for ERK1. The current
study extends our knowledge of the role of the amygdala in no-
ciception by providing evidence that ERK1 is not required for
formalin-induced mechanical hypersensitivity.
Results from thepresent study indicate that ERK1 is not required
for formalin-induced spontaneousbehavior, chronic inflammatory,
and neuropathic pain models, suggesting a predominant isoform-
specific role for ERK2. Isoform-specific functionsmay also occur in
humans, since copynumber variationof each isoformyields distinct
neurological deficits. ERK1 deletion or duplication is associated
with autism (Kumar et al., 2008), whereas reduced ERK2 expres-
sion is associated with microcephaly, cognitive deficits, and de-
velopmental delay (Newbern et al., 2008). The relevance to the
human nervous system suggests that dissecting the roles of ERK1
and ERK2 will be important for understanding and treating
chronic pain conditions.
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